Taiwan
· Delayed Price · Currency is TWD AP Biosciences Company Description
AP Biosciences Inc, a clinical-stage biopharmaceutical company, researches and develops bispecific antibody drugs for unmet medical needs.
It develops IBI302 that is in phase III clinical trials for the treatment of neovascular age-related macular degeneration; AP505 that is in phase I clinical trials for treating solid tumors; AP203 that is in phase I clinical trial for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous-cell carcinomas; AP402, which is in in the pre-clinical research phase for breast cancer patients; and AP601 that is in pre-clinical research phase for treating lung cancer, pancreatic cancer, bladder cancer, ovarian cancer, and other solid tumors.
The company was founded in 2013 and is based in Taipei City, Taiwan.
| Country | Taiwan |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 37 |
| CEO | Jeng-Horng Her |
Contact Details
Address: No. 508, Zhongxiao East Road Taipei City, 115 Taiwan | |
| Phone | 886 2 2653 2886 |
| Website | apbioinc.com |
Stock Details
| Ticker Symbol | 6945 |
| Exchange | Taipei Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0006945009 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jeng-Horng Her | Chief Executive Officer |
| Tony Lin | Chief Financial Officer |